Quantcast Destiny Pharma | Downing

Destiny Pharma

Sector: 
Growth Capital

Destiny Pharma is an innovative biotech company developing treatments for antibiotic-resistant bacteria (also known as superbugs). 

In September 2017, Downing-managed VCTs invested £1.75 million in Destiny Pharma as part of a £15.3 million funding round. The capital will primarily be used to progress the development of Destiny Pharma's 'XF-73' drug, which has shown a capability of killing bacteria rapidly and before it can develop any resistance.

On 4 September 2017, Destiny Pharma floated on the Alternative Investment Market, where it raised more than £10 million. 

Our investment was made in collaboration with BioScience Managers, a global leader in healthcare and life sciences and investment partner to the Downing FOUR VCT - Healthcare Share Class. 

Download the PDF file to read the full case study

Important Notice

Investing in our products will place your capital at risk and you may not get back the full amount invested. Any tax treatment may be subject to change and the availability and value of the reliefs depend on the individual circumstances of each investor. The availability of tax reliefs also depends on the investee companies maintaining their qualifying status.

Further information can be found at HMRC’s website. Neither past performance or forecasts are reliable indicators of future results and should not be relied upon. Unquoted or smaller company shares are likely to have higher price fluctuations and are likely to be more difficult to sell than shares quoted on the London Stock Exchange Official List. Website content is not intended to constitute investment, tax or legal advice. We recommend you seek independent advice before investing in any of our products.

Important Notice

Downing’s investments place your capital at risk and you may not get back the full amount invested. Past performance and forecasts are not a reliable guide to future results. Tax treatment may be subject to change and depends on individual circumstances. Smaller company shares are likely to have higher volatility and liquidity risks than other types of main market listed instruments. We recommend that you seek professional independent financial advice before investing. We do not offer investment or tax advice.

By clicking below you confirm you have read and understood the information above.